X.T.L. Biopharmaceuticals Partners with SK Biopharmaceuticals for AI-Driven Epilepsy Management Solutions

SK Biopharmaceuticals Expands into Digital Healthcare with AI-Driven Epilepsy Management Platform

In a significant move to enhance its portfolio in the digital healthcare landscape, SK Biopharmaceuticals, Co., Ltd. announces the formation of a joint venture called Mentis Care, Inc., in collaboration with Brazilian pharmaceutical company Eurofarma. The launch event, held on October 20, 2025, in Toronto, Canada, signifies SK Biopharmaceuticals' strategic intent to revolutionize the management of epilepsy through the integration of artificial intelligence (AI) and advanced wearable technologies. This joint venture marks a pivotal expansion for SK Biopharmaceuticals as it seeks to harness its expertise in AI-powered electroencephalography (EEG) to deliver innovative solutions for patients suffering from epilepsy.

Mentis Care aims to develop a cutting-edge platform that focuses on real-time seizure detection and personalized patient care. With the companies combining their strengths, the platform will feature clinical decision support tools designed to enhance the management of epilepsy, a condition that affects millions globally. Since 2018, SK Biopharmaceuticals has been refining its technologies in EEG and wearable devices, and this partnership allows for the practical application of those advancements. The aim is to create a comprehensive digital healthcare solution that not only detects seizures but also provides actionable insights for healthcare professionals, thereby improving patient outcomes through timely interventions.

Strategically located in the MaRS Discovery District, a hub for innovation in Toronto, Mentis Care plans to expand its team and foster collaborations with academic institutions and industry partners. This collaborative approach is crucial for the clinical validation of the AI algorithms being developed within this venture. By focusing on evidence-based outcomes and integrating advanced technology in patient care, SK Biopharmaceuticals positions itself at the forefront of a new era in epilepsy management, ultimately striving to enhance the quality of life for those affected by this neurological disorder.

In addition to this joint venture, SK Biopharmaceuticals continues to explore further opportunities within the central nervous system disorder space. Their commitment to research and development in novel therapeutic solutions aligns with the growing demand for innovative healthcare technologies. This collaborative initiative not only strengthens SK's market presence but also demonstrates the company's dedication to improving patient care through advanced digital solutions.

As SK Biopharmaceuticals embarks on this transformative journey with Mentis Care, the implications for the future of epilepsy treatment are promising. By integrating AI and wearable technology, the joint venture exemplifies the potential of digital healthcare to address chronic conditions, paving the way for a more personalized approach to patient management in the biopharmaceutical industry.